Gathering the record
Relay is organizing the evidence and source boundaries.
Copper-binding tripeptide complex
AHK-Cu is a copper complex of the tripeptide alanine-histidine-lysine, studied mainly in hair-follicle and skin-related laboratory systems.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
AHK-Cu is a copper-bound tripeptide made from alanine, histidine, and lysine. It is studied mainly in hair-follicle and skin-related laboratory systems.
Researchers are interested because isolated human scalp follicles and related cells can be used to examine whether copper-peptide signaling changes growth-related behavior before attempting a clinical study.
In an ex-vivo experiment, AHK-Cu promoted elongation of cultured human scalp follicles and changed dermal-papilla-cell behavior. The tissue was removed and treated in a laboratory; people were not given the compound, and no controlled clinical efficacy trial was located.
Skin penetration, formulation performance, visible hair outcomes, comparative effectiveness, repeated-use safety, and any injectable effect remain unknown. A response in isolated follicles does not establish that a finished product works on a living scalp.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
Published research exposed isolated human scalp follicles and cultured cells to AHK-Cu outside the body to examine growth-related laboratory changes.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Laboratory and ex vivo human-follicle evidence; no controlled clinical efficacy trial located.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Whether a standardized topical formulation improves hair outcomes in controlled human trials and how it compares with established treatments.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Participants were not treated, so this is not a human clinical administration record. The experiment cannot establish topical absorption, visible hair growth, comparative effectiveness, injectable effects, or clinical safety. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Cultured human scalp follicles exposed ex vivo showed elongation and growth-related cellular changes; participants were not treated clinically.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Whether a standardized topical formulation improves hair outcomes in controlled human trials and how it compares with established treatments.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Mechanisms
AHK-Cu has been evaluated in cultured human hair follicles and dermal-cell systems. Ex vivo human tissue is biologically relevant but is not a clinical treatment study.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
No single validated target is established in the current record.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Ex vivo human hair-follicle and cell study
Cultured human scalp follicles
AHK-Cu promoted elongation of isolated cultured human hair follicles and influenced dermal papilla cell behavior.
Study administration: Not stated in the current record.
Limitations: Ex vivo tissue study; no clinical efficacy or safety conclusion.
Narrative review
Population not stated.
Endpoints were not fully described in the current record.
A review describes copper-peptide biology and a limited direct clinical evidence base.
Study administration: Not stated in the current record.
Limitations: Mechanistic review; product and peptide-specific evidence varies.
Safety snapshot
Clinical irritation, sensitization, systemic copper exposure, and longer-term cosmetic-use safety are not adequately characterized for standardized AHK-Cu products.
No direct evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryNot FDA-approved as a drug; direct evidence is laboratory and ex vivo. Whether a standardized topical formulation improves hair outcomes in controlled human trials and how it compares with established treatments.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 17703734
PMID 35626037